Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 72162-1449

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 72162-1449). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Alfuzosin Hydrochloride shown as a 2D molecular diagram depicting its various functional groups and atoms including nitrogen, oxygen, carbon, and hydrogen arranged in its characteristic extended aromatic and side chain structure.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph depicting Alfuzosin plasma concentration (ng/mL) over time (hours) under fed and fasted conditions. The graph shows two curves with error bars: one for fed state with higher peak concentration around 8 hours, and one for fasted state with a lower and flatter concentration profile over 24 hours.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph depicting mean change from baseline in IPSS Total Symptom Score over 84 days of treatment. The x-axis represents days of treatment (0, 28, 56, 84) and the y-axis represents mean change, with negative values indicating improvement. Two treatment groups are compared: Placebo (N=167) shown by a dashed line with triangle markers, and Alfuzosin hydrochloride extended-release tablets (N=170) shown by a solid line with square markers. Alfuzosin shows a greater decrease in symptom score over time compared to placebo. Statistical significance (p < 0.001) is noted at day 84.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
Line graph depicting mean change from baseline in IPSS Total Symptom Score over 84 days of treatment comparing placebo (N=152) and Alfuzosin hydrochloride extended-release tablets (N=137). The graph shows greater symptom score reduction for Alfuzosin hydrochloride over time, with statistical significance noted at day 84 (p < 0.01).*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph showing mean change from baseline in IPSS Total Symptom Score over 84 days of treatment comparing Alfuzosin hydrochloride extended-release tablets (10 mg) with placebo. The graph depicts a greater decrease in symptom score for the Alfuzosin group versus placebo, with statistical significance noted at day 84 (p < 0.01).*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph depicting mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment comparing placebo and Alfuzosin hydrochloride extended-release tablets. The x-axis shows days of treatment (0, 28, 56, 84), and the y-axis shows mean change in mL/s. The graph includes data for placebo (dashed line with triangles) and Alfuzosin hydrochloride (solid line with squares), showing greater increase in flow rate for Alfuzosin with statistical significance at day 84 (p < 0.001).*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A line graph comparing mean change from baseline in peak urine flow rate (mL/s) over 84 days of treatment between placebo and Alfuzosin hydrochloride extended-release tablets. The graph shows mean changes increasing more with Alfuzosin than placebo, with statistical significance indicated at day 84 (p < 0.05). The x-axis represents days of treatment, and the y-axis shows mean change in mL/s.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
A line graph depicting the mean change from baseline in peak urine flow rate (mL/s) over days of treatment for a clinical trial comparing alfuzosin hydrochloride extended-release tablets and placebo. The x-axis shows days of treatment (0, 14, 28, 56, 84), and the y-axis shows mean change in mL/s. Two lines represent the two groups: one with squares for alfuzosin tablets and one with triangles for placebo, with values plotted at each time point.*
FDA Label Image

Label (Lbl721621449)

Label (Lbl721621449)
Label for Alfuzosin Hydrochloride Extended-Release Tablets USP, 10 mg strength, oral dosage form. The label states the product contains 90 tablets and is repackaged by Bryant Ranch Prepack, Burbank, CA, and manufactured by Sun Pharmaceutical Industries Ltd. Storage instructions and usage warnings are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.